352 related articles for article (PubMed ID: 27084978)
1. Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures.
Chung SS; Hogan RE; Blatt I; Lawson P B; Nguyen H; Clark AM; Anders B; Halvorsen MB;
Epilepsy Behav; 2016 Jun; 59():13-20. PubMed ID: 27084978
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of once-daily extended-release topiramate (USL255): a subgroup analysis based on the level of treatment resistance.
Hogan RE; Blatt I; Lawson B; Nagaraddi V; Fakhoury TA; Anders B; Clark AM; Laine D; Halvorsen MB; Chung SS
Epilepsy Behav; 2014 Dec; 41():136-9. PubMed ID: 25461205
[TBL] [Abstract][Full Text] [Related]
3. Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study.
Chung SS; Fakhoury TA; Hogan RE; Nagaraddi VN; Blatt I; Lawson B; Arnold S; Anders B; Clark AM; Laine D; Meadows RS; Halvorsen MB;
Epilepsia; 2014 Jul; 55(7):1077-87. PubMed ID: 24902983
[TBL] [Abstract][Full Text] [Related]
4. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
[TBL] [Abstract][Full Text] [Related]
5. USL255 extended-release topiramate for the treatment of epilepsy.
Chung S
Expert Rev Neurother; 2014 Oct; 14(10):1127-37. PubMed ID: 25220748
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
[TBL] [Abstract][Full Text] [Related]
7. Topiramate Extended Release: A Review in Epilepsy.
Hoy SM
CNS Drugs; 2016 Jun; 30(6):559-66. PubMed ID: 27224993
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
[TBL] [Abstract][Full Text] [Related]
9. USL255 extended-release topiramate: dose-proportional pharmacokinetics and tolerability in healthy volunteers.
Clark AM; Halvorsen MB; Braun TL; Johnson KM; Cloyd JC
Epilepsia; 2014 Jul; 55(7):1069-76. PubMed ID: 24861853
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
Piña-Garza JE; Lagae L; Villanueva V; Renfroe JB; Laurenza A; Williams B; Kumar D; Meador KJ
Epilepsy Behav; 2018 Jun; 83():50-58. PubMed ID: 29653338
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures.
Novotny E; Renfroe B; Yardi N; Nordli D; Ness S; Wang S; Weber T; Kurland CL; Yuen E; Eerdekens M; Venkatraman L; Nye JS; Ford L
Neurology; 2010 Mar; 74(9):714-20. PubMed ID: 20089937
[TBL] [Abstract][Full Text] [Related]
13. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
[TBL] [Abstract][Full Text] [Related]
14. Levetiracetam extended release for the treatment of patients with partial-onset seizures: A long-term, open-label follow-up study.
Chung S; Ceja H; Gawłowicz J; McShea C; Schiemann J; Lu S
Epilepsy Res; 2016 Feb; 120():7-12. PubMed ID: 26716580
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: A phase III randomized, double-blind, placebo-controlled trial.
Inoue Y; Tiamkao S; Zhou D; Cabral-Lim L; Lim KS; Lim SH; Tsai JJ; Moseley B; Wang L; Sun W; Hayakawa Y; Sasamoto H; Sano T; McClung C; Bass A
Epilepsia Open; 2024 Jun; 9(3):1007-1020. PubMed ID: 38576178
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.
Ben-Menachem E; Baulac M; Hong SB; Cleveland JM; Reichel C; Schulz AL; Wagener G; Brandt C
Epilepsy Res; 2021 Feb; 170():106526. PubMed ID: 33461041
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study.
Hufnagel A; Ben-Menachem E; Gabbai AA; Falcão A; Almeida L; Soares-da-Silva P
Epilepsy Res; 2013 Feb; 103(2-3):262-9. PubMed ID: 22871333
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.
Krauss GL; Klein P; Brandt C; Lee SK; Milanov I; Milovanovic M; Steinhoff BJ; Kamin M
Lancet Neurol; 2020 Jan; 19(1):38-48. PubMed ID: 31734103
[TBL] [Abstract][Full Text] [Related]
20. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
